Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Together: Sequential Bepirovirsen and PegIFN in Chronic Hepatitis B
NCT04676724Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2021
- Primary completion
- Feb 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 11
01
Overview
A Phase 2 trial of bepirovirsen in Chronic Hepatitis B (CHB), sponsored by GSK. Started Jan 2021; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04676724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676724.